Ixiaro - supply shortage
Ongoing
Japanese encephalitis vaccine (inactivated, adsorbed)
Shortage
Human
Shortage information
Ixiaro is a vaccine used in adults and children aged 2 months and older to help protect against Japanese encephalitis, a disease that causes inflammation of the brain.
The company that markets Ixiaro had experienced manufacturing problems, which worsened an already existing shortage of Ixiaro due to an increase in demand. The manufacturing problems have now been resolved and the supply is improving across the EU/EEA. The shortage is expected to be resolved by the end of January 2025. The shortage is not related to a safety issue.
The supply shortage affects Ireland, Italy, Poland, Portugal and Spain. For up-to-date information about the status of a medicine shortage in a particular EU/EEA Member State, consult the national shortage register or contact the national competent authority.
EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder to identify measures to mitigate the impact of the supply shortage.
The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU.
- The company marketing Ixiaro, Valneva Austria GmbH, had experienced manufacturing problems. This worsened an already existing shortage of Ixiaro caused by an increase in demand. The manufacturing problems have been resolved now and the shortage is expected to be resolved by the end of January 2025.
- The shortage of the vaccine affects Ireland, Italy, Poland, Portugal and Spain.
- Please consult your country’s national shortage register for further advice, including advice on the availability of Ixiaro in your country
- The company holding the marketing authorisation for Ixiaro, Valneva Austria GmbH, had experienced manufacturing problems. This worsened an already existing shortage of Ixiaro caused by an increase in demand. The manufacturing problems have now been resolved and the shortage is expected to be resolved by the end of January 2025.
- The shortage of the vaccine affects Ireland, Italy, Poland, Portugal and Spain.
- Please consult your doctor or pharmacist for any questions and for advice on current availability of Ixiaro.
- Alternatively you can also consult your country’s national shortage register for further information.
Key facts
- Medicines affected
- Ixiaro
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- Japanese encephalitis vaccine (inactivated, adsorbed)
- Therapeutic area (MESH)
- Encephalitis, Japanese
- Immunization
- Pharmaceutical forms affected
- Suspension for injection
- Strengths affected
- 6AU
- Availability of alternatives
- No
Key dates
- Expected resolution
- End of January 2025
- First published
- Last updated